Inner Balance HRT Review 2026: Oestra Cost, Dose Conflicts, and What to Verify Before You Pay
Ready to check the fit?
Comfortable with the compounded, cash-pay model? Check whether an Inner Balance clinician considers Oestra appropriate for your history and state. Affiliate link. Eligibility and prescribing are decided by the independent clinical practice—not The HRT Index.
This Inner Balance HRT review found a real U.S. telehealth business selling Oestra, a compounded vaginal cream with estradiol and progesterone. The published base price is $199 a month for six months, then $99.50. Oestra is not FDA-approved, and Inner Balance publishes conflicting dose, pharmacy, refund, and state information.
Best for you if:
- You have already tried an FDA-approved hormone-therapy route and it did not work for you or you could not tolerate it.
- You want estradiol and progesterone in one daily application instead of separate products.
- You accept compounded medication and can comfortably pay $199 a month for the first six months.
- You will verify your exact formula, pharmacy, state access, and refund terms in writing before relying on them.
Not for you if:
- You want an FDA-approved finished drug with a published label and dose you can look up.
- You want to use insurance. Inner Balance is direct-pay and its terms say patients must not submit claims to private insurance, Medicare, or Medicaid.
- You are 12 or more months past your final period and are bleeding. Go to the bleeding section; this is not a shopping decision.
- You want an in-person examination or included laboratory testing.
- You need to adjust estrogen and progesterone independently.
The 30-second verdict
| Decision point | What we found | Why it matters | Status |
|---|---|---|---|
| What it is | A prescription compounded vaginal cream containing estradiol and micronized progesterone | Compounded means made by a compounder to a prescription. It does not mean FDA-approved | Verified |
| Published base cost | $199/month for six months, then $99.50/month: $1,791 in year one | The $99.50 headline is not the rate paid during the first six months | Verified; math calculated by The HRT Index |
| FDA status | Oestra is not FDA-approved | FDA has not reviewed this finished product for safety, effectiveness, or quality before marketing | Verified |
| Insurance | Direct-pay only; HSA/FSA accepted at checkout | A hard stop if insurance billing is required | Verified |
| Biggest unresolved issue | Live Inner Balance pages describe the pharmacy pathway as both 503A and 503B | Those are different federal compounding pathways with different requirements | Conflicting |
| Second biggest issue | Inner Balance publishes multiple Oestra strengths | The public website does not tell you which formula will be prescribed to you | Conflicting until confirmed for the individual prescription |
Last verified: August 10, 2026. The HRT Index editorial research — not medically reviewed by a clinician. Educational only; not medical advice.
Our money disclosure, up front: The HRT Index may earn a commission if you start with Inner Balance. That does not change the price you pay. We published the conflicts, limitations, and wrong-fit routes below because the page is useless if it only tells you why to click.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
What did The HRT Index actually verify?
We checked Inner Balance's live product, treatment, help-center, FAQ, HSA/FSA, refund, review, and comparison pages on August 10, 2026, then checked the regulatory and medical claims against FDA, ACOG, The Menopause Society, DailyMed, and peer-reviewed literature. The result is a provider-stated-versus-verified record, not a score.
What we confirmed
- The live base price: $199 per month for six months, then $99.50 per month.
- The first-year base-cost math: $1,791 before any separately charged dose change, laboratory work, or other product.
- Oestra is a compounded prescription product and is not FDA-approved.
- The product page lists 3 mg estradiol plus 100 mg micronized progesterone per pump.
- A live Inner Balance help-center page lists two other formulations: 0.5 mg/50 mg and approximately 2 mg/80 mg.
- The refund policy requires two separate deadlines and says a refund is not triggered automatically by cancellation.
- HSA/FSA payments are accepted, but the live refund policy and HSA/FSA page give opposite answers about refund eligibility.
- Inner Balance's product page describes a 90-day supply, while its subscription terms provide for monthly subscription charges.
- The provider's checkout explanation says checkout happens before the clinician's final review.
- The live site publishes conflicting claims about 503A versus 503B, state coverage, founder licensure, and some outcome figures.
- Trustpilot currently shows 3.1/5 from 15 reviews for
www.innerbalance.com; the BBB profile is not accredited and currently shows a B- rating with 12 complaints.
What we could not verify
- The legal name and location of the pharmacy that will fill an individual Oestra prescription.
- Whether that individual prescription is compounded under section 503A or by a registered 503B outsourcing facility.
- Which published Oestra formula a new patient will actually receive.
- Product-specific pharmacokinetic data for the exact finished formulation and dose prescribed.
- Product-specific evidence demonstrating endometrial protection for the exact finished formulation and regimen.
- A public endometrial-monitoring protocol specific to Oestra.
- The public cash price of optional laboratory testing.
- The amount of any additional charge for a dose adjustment. The live pricing page says adjustments may cost more but does not publish the amount.
- A reconciled, state-by-state availability list.
- The collection method, denominator, and moderation process behind the 5,695-review figure displayed on Inner Balance's own site.
Those are not side notes. They are the questions that determine whether this is a clean fit or a $1,791 experiment you never felt comfortable with.
Is Inner Balance legit?
Inner Balance is a real operating telehealth business with a Boise, Idaho address, a live prescription workflow, and a BBB business profile. Its site says licensed clinicians review prescriptions and displays pharmacy and telehealth credential badges. That establishes a functioning business; it does not make Oestra FDA-approved or resolve which pharmacy compounds it.
The word legit gets used to mean five different things at once. Break it apart and the answer gets useful.
1. Is the company real? Yes. The BBB profile lists Inner Balance Health PLLC at 827 E Park Blvd, Suite 200, Boise, Idaho. Inner Balance's terms identify separate business and clinical entities.
2. Is a clinician involved? The provider says a licensed clinician reviews the health assessment and decides whether to prescribe. Its terms describe independent clinical practices exercising their own medical judgment.
3. Is the dispensing pharmacy identifiable from the public site? No. Inner Balance says the product is compounded by a licensed U.S. pharmacy, but we did not find the pharmacy's legal name and location on the public pages we reviewed.
4. Is the compounding pathway clear? No. The product and treatment pages display a 503A pharmacy badge, while treatment-page FAQs say Oestra is made by a 503B outsourcing facility. That conflict matters.
5. Is Oestra FDA-approved? No. FDA states that compounded drugs are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, and quality.
What does the LegitScript badge prove?
Inner Balance displays a LegitScript certification seal that links to LegitScript's verification tool. That is a useful commercial-legitimacy signal, but it does not answer the medication question: LegitScript status is not FDA approval, is not pharmacy identification, and does not resolve whether the prescription is filled under 503A or 503B.
Who is Dr. Sarah Daccarett?
Inner Balance identifies Sarah Daccarett, MD, as its founder and CEO and describes her as a board-certified physician specializing in women's hormonal health and longevity medicine. Its live pages currently conflict on whether she is licensed in 48 or 50 states.
We did not independently verify every specialty or state-license claim in this review. More important: do not assume the founder is the clinician who will review your file. Ask for the name of the actual prescriber and verify that clinician through your state medical board.
What does the BBB file show?
The BBB profile for Inner Balance Health PLLC is not accredited. As of August 10, 2026, it shows a B- rating and 12 complaints.
BBB complaints are allegations, not adjudicated facts. Inner Balance has responded to complaints on the profile. The recurring service themes are still useful:
- Confusion about recurring subscription charges.
- Cancellation and refund friction.
- Difficulty reaching a person.
- Confusion about when payment occurs relative to identity verification and clinical review.
That last point maps to something the provider itself confirms: the site says a candidate moves to checkout and a licensed clinician reviews the information afterward.
Before you pay, save the questions instead of trusting your memory. The exact checklist is in The 12 questions to ask before you pay.
How much does Inner Balance HRT cost?
Oestra's published base price is $199 per month for the first six months and $99.50 per month after that. The first-year base cost is $1,791, or $149.25 per month when averaged across year one. Laboratory work and some dose adjustments may cost extra, but Inner Balance does not publish those amounts.
The provider's product page leads with "From $99.50/mo." That is the ongoing rate after six months, not the rate a new patient pays.
The full published cost curve
| Time on service | Total base cost paid | Blended monthly cost | What the headline rate hides |
|---|---|---|---|
| 1 month | $199.00 | $199.00 | The $99.50 rate is not available yet |
| 3 months | $597.00 | $199.00 | One 90-day shipment is paid across three monthly charges |
| 6 months | $1,194.00 | $199.00 | End of the higher-price period |
| 12 months | $1,791.00 | $149.25 | The honest year-one comparison number |
| 24 months | $2,985.00 | $124.38 | Two years are needed to bring the blended rate near $124 |
| 36 months | $4,179.00 | $116.08 | Still before any extra dose, lab, or add-on charge |
Calculated by The HRT Index from Inner Balance's published rates on August 10, 2026. This is subscription math, not an individual quote.
Why do some Inner Balance pages say $99 and $1,788?
Inner Balance's main product and treatment pages say $99.50 after month six. Some of its own comparison articles say $99 and calculate a first-year total of $1,788.
Six months at $199 plus six months at $99.50 equals $1,791.
It is three dollars. Nobody is being robbed. But a provider selling prescription care should be able to make its own rate card agree with itself.
What is included?
The live pricing page lists:
- Prescription treatment.
- Pharmacy processing and shipping.
- Unlimited clinical follow-up.
- HSA/FSA payment at checkout.
- A 20% Fullscript supplement discount.
- Dose adjustments if needed.
The asterisk matters: the same page says dose adjustments may incur an additional cost. The amount is not published.
What is not included in the verified base cost?
- Optional laboratory testing.
- Any extra amount charged for a dose adjustment.
- Other Inner Balance products.
- Outside examinations, imaging, or procedures.
- Any medication filled through a pharmacy the patient separately chooses under the terms.
The billing mechanic that catches people
Inner Balance's product page describes a 90-day supply, and its subscription terms provide for monthly charges. Those terms also say that if a customer receives three months of Oestra and cancels before payment is collected for all three months, the company may charge a reactivation fee if that person later restarts.
That is not the same as a three-month prepaid charge, but it does mean "cancel anytime" is not the whole billing story. Save the terms you agreed to, the shipment date, every charge, and the cancellation confirmation.
Does the combined product, cash-pay model, and $1,791 first-year base cost still fit? Check Inner Balance's current pricing and eligibility before relying on a screenshot or review.
Which HRT provider is actually right for you?
The right provider depends on the symptoms being treated, whether you have a uterus, medication route, medical history, insurance, state, and whether compounded or FDA-approved medication is the priority. Inner Balance is one specific care model, not the universal answer.
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
What's actually in Oestra?
Oestra is a compounded vaginal cream that Inner Balance says contains estradiol and micronized progesterone and is intended for systemic absorption. The problem is not that only one strength exists: it is that several live Inner Balance pages publish different strengths without clearly explaining which formula a new patient receives or how the options map to the public price.
The live dose problem
| Inner Balance source | Estradiol stated | Progesterone stated | What is missing |
|---|---|---|---|
| Main product page | 3 mg per pump | 100 mg per pump | Whether this is the universal starting formula |
| Help center: Oestra Menopause | 0.5 mg | 50 mg | Public price and eligibility criteria for this version |
| Help center: Oestra Start | Approximately 2 mg | Approximately 80 mg | Why the "Start" formula differs from the main product-page formula |
| Help center: percentage listing | 0.3% | 10% | Pump volume needed to convert concentration into milligrams |
The highest published estradiol amount is six times the lowest. That does not prove a dispensing error. Compounded prescriptions can legitimately differ by patient and stage. It does prove the public site cannot tell you what will be in your bottle.
Ask for the exact milligrams per pump on your prescription label. Do not settle for a percentage without pump volume, a product-family name, or "personalized" as the whole answer.
Can you compare an Oestra pump directly with an estradiol patch or ring?
No. Total milligrams in a container, milligrams per pump, and a product's controlled daily release rate are not interchangeable. Raw content cannot tell you how much reaches the bloodstream or tissue.
The honest comparison is not a scary dose multiple. It is how much product-specific information exists.
| Product or model | Regulatory status | Route and labeled use | Public dose information | FDA-reviewed product information |
|---|---|---|---|---|
| Oestra | Compounded; not FDA-approved | Vaginal cream marketed by Inner Balance for systemic effects | Multiple amounts across live pages | No FDA-approved label |
| Femring | FDA-approved | Vaginal ring labeled for systemic menopausal indications | Releases 0.05 or 0.10 mg estradiol/day | Yes |
| Estring | FDA-approved | Vaginal ring labeled for genitourinary symptoms | Releases 7.5 mcg estradiol/day | Yes |
| Vagifem/Yuvafem | FDA-approved products | Vaginal insert labeled for genitourinary symptoms | 10 mcg per insert | Yes |
| Imvexxy | FDA-approved | Vaginal insert labeled for dyspareunia | 4 or 10 mcg | Yes |
| Estradiol vaginal cream 0.01% | FDA-approved products and generics | Vaginal cream labeled for vulvar/vaginal symptoms | 0.1 mg estradiol per gram | Yes |
| Oral micronized progesterone products | FDA-approved products and generics | Oral capsule used when clinically appropriate | Common labeled strengths include 100 and 200 mg | Yes |
"Vaginal" does not automatically mean local-only, and "local indication" does not mean zero systemic absorption. The distinction above is what the FDA-approved product is labeled to treat and whether product-specific prescribing information exists.
The strongest honest reason Oestra exists
Some women using systemic hormone therapy manage separate estrogen and progestogen products and may also need a local vaginal treatment. Oestra puts estradiol and progesterone into one vaginal cream.
Our search of FDA product resources on August 10, 2026, found no FDA-approved vaginal cream combining estradiol and progesterone in one finished product. That is a real convenience gap.
The tradeoff nobody mentions
One product is simpler. It is also less independently adjustable.
If the estradiol component is working but the progesterone component is not tolerable, a fixed combination does not let the patient change one without revisiting the whole formula. If the preferred route is a patch plus oral progesterone, Oestra cannot become that route.
That is not a slogan against compounding. It is the design tradeoff.
Is Oestra FDA-approved?
No. Oestra is a compounded prescription product, not an FDA-approved finished drug. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Estradiol and progesterone appearing in other approved products does not transfer approval to Oestra's combined finished formulation.
This distinction is the page's hardest line.
"FDA-approved ingredients" does not make a compounded product approved
FDA approves finished drug products for defined uses, strengths, manufacturers, and labeling. A compounded product does not become FDA-approved because its component molecules are used in other FDA-approved drugs.
FDA has also warned telehealth companies against claims implying that a compounded product is the same as an FDA-approved drug or obscuring the product's compounded sourcing.
Oestra's site uses phrases including "FDA-approved hormones" and "clinically proven." Those phrases can blur the line. The accurate description is:
Oestra contains compounded estradiol and micronized progesterone. Oestra itself is not FDA-approved, and the finished Oestra formulation has no FDA-approved prescribing label.
What do 503A and 503B mean?
| Pathway | General model | Federal quality framework | What it does not mean |
|---|---|---|---|
| 503A | Patient-specific compounding by a state-licensed pharmacy, federal facility, or physician when statutory conditions are met | Primarily state pharmacy oversight; qualifying 503A compounding is not subject to federal CGMP requirements | FDA-approved |
| 503B | A facility elects to register with FDA as an outsourcing facility | Subject to CGMP requirements, FDA registration, adverse-event and product reporting, and risk-based FDA inspection | FDA-approved or guaranteed compliant |
A 503B registration is not an FDA approval. A 503A pharmacy is not outside all federal law. FDA's compounding Q&A and outsourcing-facility guidance show why the categories are different enough that the provider should identify which one applies and name the facility.
Inner Balance says both
The live product and treatment pages display a 503A pharmacy badge. Live treatment-page FAQ copy says Oestra is made by a 503B FDA-regulated compounding pharmacy.
We are not going to pick the answer that converts better. Ask:
"Is my Oestra prescription compounded under section 503A or by a registered 503B outsourcing facility, and what is the pharmacy's legal name and location?"
Then verify any claimed 503B facility against FDA's current registered-outsourcing-facility list.
If you already tried an FDA-approved route and the one-combined-cream model is the point, not an accident, this may still be your lane. Check Inner Balance eligibility and current availability.
Want a published FDA-approved dose instead? See our Hers menopause review. Want to use insurance? See our Midi Health review.
Did the FDA's 2025 and 2026 hormone-therapy labeling changes apply to Oestra?
No. FDA initiated menopausal hormone-therapy labeling changes in November 2025 and approved the first six revised labels in February 2026. Those actions apply to FDA-approved products and their application holders. They did not approve Oestra, create an FDA-reviewed Oestra label, or validate Oestra's product-specific claims.
The draft originally stopped at the November 2025 announcement. That is now incomplete: on February 12, 2026, FDA announced approval of revised labeling for six menopausal hormone-therapy products, with additional application holders having submitted changes.
| Question | Verified answer |
|---|---|
| What happened in November 2025? | FDA initiated a process to revise boxed-warning language for menopausal hormone-therapy products |
| What happened in February 2026? | FDA approved revised labeling for an initial six products |
| Which products are governed? | FDA-approved products held under approved applications |
| Did every hormone-therapy label change at once? | No. FDA described an initial batch and additional submitted changes |
| Did Oestra gain FDA approval or FDA-reviewed labeling? | No |
| Did the action erase individualized risk review for systemic therapy? | No |
The Menopause Society specifically agreed with removing the boxed warning from low-dose vaginal estrogen used for genitourinary symptoms and separately said systemic estrogen still carries potential risks in some individuals that should be reviewed in detail.
Inner Balance markets Oestra as vaginally applied and systemically absorbed. That is not the same category as a low-dose local vaginal estrogen product simply because both go in the vagina.
Take the good news for what it is. Do not stretch it into a product endorsement the FDA never made.
Where do Inner Balance's own pages conflict?
The most consequential conflicts are current and reproducible: pharmacy pathway, dose, price, refund eligibility for HSA/FSA purchases, state coverage, and founder licensure. Other pages use unreconciled outcome sets and language that can make Oestra sound as though it contains testosterone when its ingredient listing does not.
The HRT Index conflict ledger — verified August 10, 2026
| # | Decision question | Statement A | Statement B | Reader impact |
|---|---|---|---|---|
| 1 | 503A or 503B? | Product/treatment badges say 503A | Treatment FAQ says 503B | You cannot identify the applicable compounding pathway |
| 2 | What dose is one pump? | Product page: 3 mg estradiol + 100 mg progesterone | Help center: 0.5/50 and approximately 2/80 | You cannot know the starting formula from the public site |
| 3 | What is month seven? | $99.50/month | $99/month in provider comparison articles | Small dollar difference; real rate-card inconsistency |
| 4 | What is year one? | Published current rate produces $1,791 | Some provider articles say $1,788 | The provider's own annual math does not match its current rate |
| 5 | Can an HSA/FSA purchase be refunded? | Refund policy says eligible | HSA/FSA page says non-refundable and excluded | Material conflict if the guarantee is part of the decision |
| 6 | Where is care available? | Pages say 43 states plus D.C. | Other pages say 48 or all 50 states | State eligibility cannot be settled before intake |
| 7 | How many states is the founder licensed in? | Some pages say 48 | Others say 50 | Credential copy is not internally controlled |
| 8 | Does Oestra contain testosterone? | Product page says no added testosterone | FAQ says one pump "delivers" testosterone via conversion | Ingredient status and downstream physiology are blurred |
| 9 | What outcomes were reported? | Main page: 98/81/80/85/80% across named outcomes | Other company pages use 97/80.2/78.7/67.6/63% | Different internal data sets are not reconciled with sample sizes or protocols |
| 10 | Is the refund "no questions asked"? | Marketing says no questions asked | Policy requires eligibility, secure-chat request, two deadlines, exclusions, and one refund per customer | Marketing line is materially less complete than the policy |
None of this proves fraud. It proves the website is not a reliable single source for the details a patient is being asked to buy. The ledger is reproducible from Inner Balance's product page, HRT page, dose help page, refund policy, HSA/FSA page, and company comparison pages that variously claim 43 states plus D.C., 48 states, and all 50 states.
What about the outcome percentages?
The live main product/treatment page currently publishes:
- 98% improved vaginal dryness.
- 81% improved sleep quality.
- 80% improved mood.
- 85% sharper focus and vitality.
- 80% improved energy.
Other live Inner Balance articles publish a different set, including 97% for vaginal dryness, 80.2% for sleep, 78.7% for mental health, 67.6% for brain fog, and 63% for energy.
We found no linked protocol, sample size, control group, prespecified endpoints, attrition data, or peer-reviewed report for either set. Treat them as provider-reported internal outcomes, not proof of efficacy and not a forecast of an individual result.
The practical move is simple:
Screenshot the exact claim you are relying on before you pay.
Marketing pages change. Your own dated copy does not.
Is Oestra safe?
No public source we found can answer "Is Oestra safe?" with a universal yes. Estradiol and progesterone are well-studied in approved products, but Oestra's exact compounded formulation, dose, route, and regimen lack FDA-reviewed product information and publicly linked product-specific absorption and endometrial-safety data. Safety depends on the patient and the prescription.
The useful questions are narrower.
What are the two product-specific evidence gaps?
1. Systemic exposure. Inner Balance markets Oestra for systemic absorption and publishes very strong absorption claims. We found no publicly linked pharmacokinetic study measuring exposure from the exact finished Oestra formula at the published doses.
2. Endometrial protection. For a patient with a uterus, systemic estrogen ordinarily requires adequate progestogen to reduce endometrial risk. The public evidence does not establish that Oestra's exact compounded progesterone formulation and regimen provides adequate protection for every published Oestra estradiol strength.
What does the vaginal-progesterone evidence actually show?
| Evidence | What it studied | What it means here |
|---|---|---|
| Stute et al. systematic review | Vaginal micronized progesterone regimens across published studies | Suggested some off-label regimens may protect the endometrium; it did not study Oestra |
| ELITE endometrial analysis | Oral estradiol plus 45 mg vaginal progesterone gel for 10 days/month | That regimen did not completely oppose the estradiol effect; different product and regimen, but a reason not to infer protection from route or milligrams alone |
| The Menopause Society position statement | Compounded hormone therapy generally | Notes safety concerns including under- or overdosing, lack of efficacy/safety data, and lack of an approved risk label |
| FDA compounding guidance | Compounded products generally | Confirms no FDA premarket review of the finished product |
Do not compare Oestra's progesterone milligrams with a different gel and declare it safe. Do not compare them and declare it unsafe. Both shortcuts are bad science.
Ask the prescriber what evidence supports the exact estrogen-to-progesterone regimen on your label.
Does "no labs required" mean the care is unsafe?
Not by itself. Routine serum hormone testing is not required for every standard menopausal hormone-therapy decision, and symptom-led care is common; treatment still requires individualized history and risk review under The Menopause Society's guidance.
But a blood test is not an endometrial evaluation. If you have a uterus, ask:
"What is your plan for evaluating unexpected bleeding and for deciding whether my endometrium needs assessment?"
The problem is not the absence of a ritual lab panel. The problem is pretending one blanket slogan settles every monitoring question.
How should you read "clinically proven" and absorption claims?
Inner Balance uses phrases including "clinically proven," "nearly full absorption," "fewer side effects," and categorical long-term safety language.
We did not find product-specific evidence that substantiates those broad claims for Oestra as a finished compounded product. Third-party potency testing can help determine whether a batch matches a target strength. It does not prove clinical effectiveness, systemic safety, or endometrial protection.
What if you have had a hysterectomy?
Inner Balance lists post-hysterectomy women as possible candidates for a fixed estradiol-plus-progesterone formula.
The usual reason to add a progestogen to systemic estrogen is to protect an intact endometrium. Exceptions can exist, including some cases involving residual endometrium or endometriosis. Ask the prescriber:
"What specific benefit justifies the progesterone component in my case?"
Do not pay for a fixed combination without knowing why both parts are there.
What if you are breastfeeding?
Oestra has no FDA-reviewed lactation section. FDA-approved estradiol vaginal-cream labeling warns that estrogen is present in human milk and may reduce milk production and says the product should not be used during lactation.
That label is not an Oestra label, so it cannot be copied onto Oestra as though the products were equivalent. It does establish why a provider-specific postpartum marketing claim is not enough. Breastfeeding use needs individual clinical review before treatment, not a landing-page reassurance.
What about endometriosis, PCOS, or postpartum symptoms?
Inner Balance markets Oestra across menopause, perimenopause, endometriosis, PCOS, and postpartum pages. Those are not one diagnosis and do not have one interchangeable evidence base.
The public pages we reviewed do not provide product-specific controlled evidence establishing Oestra as a treatment for each condition. A patient searching for one of those diagnoses needs the diagnosis and treatment plan evaluated on its own terms.
If you bleed on Oestra, this part is not optional
Inner Balance help-center content says postmenopausal bleeding can happen with Oestra and at points describes light bleeding as temporary or not dangerous.
ACOG's April 16, 2026 guidance recommends transvaginal ultrasound plus endometrial tissue sampling as part of the initial evaluation for most patients with postmenopausal bleeding. ACOG defines postmenopausal bleeding as bleeding presumed to come from the uterus 12 or more months after the final menstrual period and notes that approximately 90% of people diagnosed with endometrial cancer have postmenopausal bleeding.
Most postmenopausal bleeding is not cancer. That is exactly why it gets evaluated instead of guessed at.
A portal message can start the conversation. It cannot perform the examination, imaging, or sampling.
If you are postmenopausal and bleeding, stop treating this as a provider-comparison question and contact a clinician who can evaluate you.
The damaging admission, without the sales fog: Inner Balance cannot give you an FDA-reviewed Oestra label because Oestra is compounded. If published prescribing information and product-specific approved data are what let you feel safe, choose an FDA-approved route through Hers, Midi, or an in-person clinician.
The other side is real: compounding is what allows a clinician to put estradiol and progesterone into one vaginal cream and alter the formula. If you already tried approved routes and that flexibility is the reason you are here, check whether Inner Balance's model fits your situation.
How does signing up work, and when do you pay?
Inner Balance's live checkout explanation says you complete a short health assessment, move to checkout if the system identifies you as a candidate, and then have the information reviewed by a licensed clinician. If the clinician approves treatment, the prescription is sent for compounding and shipment. Payment therefore comes before the final clinical decision.
| Step | What happens | What to verify |
|---|---|---|
| 1 | Complete the online health assessment | Whether your state and condition are currently served |
| 2 | Move to checkout and enter payment | Whether the card is charged or authorized immediately |
| 3 | Complete any required identity verification | What documents are accepted and what happens if verification fails |
| 4 | Licensed clinician reviews the information | Clinician's name, license, and communication method |
| 5 | If approved, prescription goes to the compounder | Pharmacy legal name, location, 503A/503B status, exact formula |
| 6 | Pharmacy prepares and ships the medication | Inner Balance says compounding/shipment usually takes 3–5 business days after approval, then delivery usually takes another 3–5 business days |
Inner Balance's terms say it may decline the agreement and return subscription fees. The public pages do not clearly state how quickly that return occurs, whether the initial transaction is an authorization or settled charge, or what is retained if identity verification cannot be completed.
Ask before putting a card into a flow you are not willing to finish.
How do cancellation and the money-back guarantee work?
Cancellation and refund are separate actions. The current refund policy says an eligible Oestra customer may request up to six months of subscription fees, but the request must be sent through secure chat within six months of the original order and within 14 days after cancellation. Cancelling alone does not create a refund request.
Cancel is not refund
- Log in to the Inner Balance account.
- Cancel through the account portal.
- Save a screenshot of the cancellation confirmation with the date visible.
- Separately send the Care Team a refund request through secure chat.
- Confirm that the request was sent within six months of the original order.
- Confirm that it was also sent within 14 days after cancellation.
- Save the request, response, and every promised refund amount.
Two clocks. One starts with the original order. The other starts when you cancel.
What does the written guarantee exclude?
- More than six months of subscription fees.
- A second refund for the same customer.
- Charges reimbursed by private insurance, Medicare, or Medicaid.
- Supplements.
- Laboratory tests.
- Third-party services.
- Libida.
- NAD+.
- BodyMatched purchases outside that product's separate stated terms.
The marketing says "no questions asked." The written policy says the customer must qualify, use a specific channel, meet two deadlines, and fit the exclusions. Read the policy, not the mood of the button.
Are HSA and FSA purchases refundable?
Inner Balance's two live pages currently disagree:
- The refund policy says HSA/FSA purchases are eligible for a refund.
- The HSA/FSA page says HSA/FSA purchases are non-refundable and not valid under the six-month guarantee.
That is a material policy conflict. Get the answer in writing before paying with an HSA or FSA card if the guarantee affects your decision.
Does Inner Balance take insurance?
No. Inner Balance says it does not accept private insurance, Medicare, or Medicaid. Its terms also say the patient agrees not to submit claims for reimbursement.
If coverage is required, stop trying to make this model fit. See the Midi Health review or use Find My HRT Path to route by insurance and state.
Already comfortable with the policy and the two deadlines? See Inner Balance's current pricing and terms.
Still uneasy? Good. Unease is useful when the site has not answered the question. Save the policy and get the HSA/FSA answer in writing first.
What do Inner Balance reviews actually show?
Inner Balance displays 4.9/5 from 5,695 reviews on its own site. Trustpilot currently shows 3.1/5 from 15 reviews for the official www.innerbalance.com domain, and BBB shows a non-accredited B- profile with 12 complaints. These pools use different methods and sample sizes, so they should never be averaged into one verdict.
| Source | Current public record | What it can tell you | What it cannot tell you |
|---|---|---|---|
| Inner Balance's own site | 4.9/5 from 5,695 reviews; "trusted by 60,000+ women" | What the provider chooses to display | Independent rating, collection method, denominator, moderation |
| Trustpilot: www.innerbalance.com | 3.1/5 from 15 reviews; profile says no history of asking for reviews | Recurring service themes in a small external pool | A reliable treatment-success rate |
| BBB | B-, not accredited, 12 complaints | Complaint themes and company responses | Proof every allegation is true |
| ConsumerAffairs | Very small review pool plus editorial summary | Another service-experience source | A clinically representative sample |
A second Trustpilot profile exists for a different domain with U.K.-facing details. We did not treat it as the official Inner Balance record.
What do people praise?
The small external pool includes praise for:
- Simplicity of the telehealth process.
- Prompt replies in some cases.
- A refund that was completed after follow-up.
- The convenience of one product.
- Individual reports of symptom improvement.
What do people complain about?
Recurring complaints include:
- Refund requests not being understood as separate from cancellation.
- Recurring billing and restart pricing.
- No live phone support.
- AI or message-based support friction.
- Identity-verification problems.
- Pump operation and irritation.
- Difficulty getting dose questions resolved.
Three current service-experience snippets
These are not medical evidence and do not show typical results.
KWilton, Trustpilot, March 2026: the refund process was "smooth and quick."
Cheryl, Trustpilot, updated April 2026: "they did the refund!"
Katie Gustafson, Trustpilot, April 2026: "No help at all, except AI."
That is the review record in miniature: some people report the policy working, others report getting stuck in the process. The written steps matter more than the average.
Reviews cannot settle the dose, pharmacy, or endometrial-evidence questions. Use them to understand service friction, then check eligibility with Inner Balance only if the care model still fits.
Who is Inner Balance right for, and who should go elsewhere?
Inner Balance is a plausible fit for a cash-pay woman who deliberately accepts compounded therapy, values one combined vaginal product, and will verify the pharmacy and exact formula. A different route fits better when the priority is FDA-approved medication, insurance, separate dose control, an in-person examination, or a clear state-access answer.
| If this is you | Start here | Why |
|---|---|---|
| Tried FDA-approved routes and could not find a tolerable or workable regimen | Inner Balance may be worth evaluating | This is the strongest clinical-use case for individualized compounding |
| Want estradiol and progesterone in one vaginal cream | Inner Balance may be worth evaluating | No FDA-approved product in our search offers this exact format |
| Want a published FDA-approved label and dose | Hers or another FDA-approved route | Oestra cannot provide an approved finished-product label |
| Want to use insurance | Midi Health or an in-network clinician | Inner Balance does not bill insurance |
| Want independent control over estrogen and progesterone | Route-flexible prescriber | A fixed combination ties the components together |
| Want an in-person exam or local workup | Local gynecology or menopause clinician | Questionnaire care cannot perform an examination |
| Want a lower-cost one-off clinician visit | Sesame Care | Marketplace care may fit better than a medication subscription |
| Postmenopausal and bleeding | A clinician who can evaluate you | Not a shopping decision |
| Not sure which row is yours | Find My HRT Path | Routes by symptoms, uterus status, medication preference, insurance, state, and safety flags |
Compare care models, not logos
| Priority | Inner Balance model | Better-fit model when this is the priority |
|---|---|---|
| One compounded combined product | Strongest fit | — |
| FDA-approved finished medication | Weak fit | FDA-approved telehealth or in-person prescribing |
| Insurance billing | Not offered | In-network menopause telehealth or local care |
| Separate estrogen/progesterone routes | Limited by fixed combination | Route-flexible prescriber |
| One-off consultation | Subscription model | Marketplace or independent clinician |
| Physical examination or imaging | Not available through the website | Local clinical care |
Why Winona is not the main alternative here
Winona also leans heavily on compounded medication. Comparing one compounded-primary provider with another does not resolve the central question on this page: whether the reader wants a compounded combined cream at all.
The clean alternative is determined by the blocker:
- FDA-approved finished drug → use an FDA-approved route.
- Insurance → use an insurance-billing provider.
- In-person evaluation → use local care.
- One-combined-cream convenience after standard routes failed → evaluate Inner Balance.
Found yourself in the first two rows? Check Inner Balance's current eligibility and state access.
Found yourself lower down? Find My HRT Path keeps the decision inside the right care model instead of forcing this one.
The 12 questions to ask before you pay
Twelve material details cannot be settled cleanly from Inner Balance's public pages. Getting the answers in writing turns this from a trust fall into an ordinary prescription decision: exact product, exact pharmacy, exact price, exact policy, and a plan for what happens if the treatment does not fit.
Copy these:
- What is the legal name and location of the pharmacy that will fill my prescription?
- Is my prescription compounded under section 503A or by a registered 503B outsourcing facility?
- Exactly how many milligrams of estradiol and progesterone will one pump of my prescription deliver?
- Which public Oestra formula corresponds to my prescription: 3/100, 0.5/50, approximately 2/80, or another formula?
- Do you have pharmacokinetic data for this exact finished formula and dose?
- If I have a uterus, what evidence supports endometrial protection for this exact regimen, and what is the plan if I bleed?
- Can the estradiol and progesterone components be adjusted separately?
- If my dose changes, what exact additional charge applies?
- Are laboratory tests included? If not, what is the cash price before I authorize them?
- If I pay with an HSA or FSA card, am I eligible for the six-month refund under the policy that will govern my purchase?
- Do you currently prescribe and ship Oestra in my state?
- What is the exact final calendar date for my refund request, and do I need to cancel before sending it?
If the care team answers clearly and the model still fits, the decision gets easier.
If they cannot answer, that is not a communication inconvenience. That is the answer.
How did The HRT Index verify this review?
The HRT Index checked live provider pages and policies, separated provider-stated claims from externally verifiable facts, recalculated the price curve, compared contradictory copy across the site, and checked medical and regulatory claims against primary sources. No product was purchased, no first-person treatment result is claimed, and no provider score was invented.
We use The HRT Index Verification Standard:
- Read every public price and calculate the real time-based cost.
- Keep FDA-approved and compounded products strictly separate.
- Verify insurance, state availability, laboratory inclusion, cancellation, and refund terms.
- Compare marketing claims with the provider's own terms and policies.
- Check medical and regulatory claims against FDA, professional-society, label, and peer-reviewed sources.
- Re-check top providers monthly and the full roster quarterly.
We evaluate providers on exactly five pillars, in this order:
- Clinical legitimacy — real entities, prescribing workflow, clinician involvement, pharmacy transparency, regulatory distinctions.
- Care quality — access to the actual prescriber, communication, follow-up, escalation, examination limits.
- Medication fit — route, formulation, FDA status, ability to adjust, evidence and monitoring needs.
- Price transparency — base price, time-based cost, add-ons, billing cadence, cancellation and refund mechanics.
- Access — states, insurance, HSA/FSA, appointment model, shipping, and practical eligibility.
Inner Balance under the five pillars
Clinical legitimacy: Real operating business and prescription workflow. The unresolved pharmacy identity and 503A/503B conflict are material gaps.
Care quality: Unlimited messaging and ongoing follow-up are advertised. The model is asynchronous and cannot provide an in-person examination; external reviews show mixed experiences getting human help.
Medication fit: The one-combined-cream format is genuinely distinctive. The public dose record is inconsistent, and the exact finished product lacks an FDA-approved label.
Price transparency: Base price is easy to find, and the year-one math is straightforward. Extra dose cost, laboratory cost, and some policy details are not.
Access: Direct-pay and HSA/FSA checkout are clear. Exact state coverage is not; the site's own pages publish 43 plus D.C., 48, and 50.
What we did not do
We did not buy Oestra. We do not have first-person experience with the medication, pump, portal, prescribing encounter, cancellation flow, or refund.
This review is editorial document verification. It is not clinical review and is not medical advice.
Inner Balance HRT review: frequently asked questions
Is Inner Balance legit?
Yes, as an operating business. It has a live U.S. telehealth workflow, a Boise business profile, and a provider-stated licensed-clinician prescription process. The separate medication question is different: Oestra is compounded and not FDA-approved.
Is Oestra FDA-approved?
No. Oestra is a compounded finished product. FDA does not review compounded drugs for safety, effectiveness, or quality before marketing.
How much is Inner Balance per month?
The published base price is $199 per month for the first six months, then $99.50 per month. That equals $1,791 in year one before any separately charged dose adjustment, laboratory work, or other product.
Does Inner Balance take insurance?
No. It is direct-pay, and its terms say patients agree not to submit claims to private insurance, Medicare, or Medicaid. HSA/FSA cards are accepted at checkout.
How do I cancel Inner Balance?
Cancel through the account portal and save the confirmation. If you want a refund, send a separate request through secure chat within six months of the original order and within 14 days after cancellation.
Are HSA/FSA purchases refundable?
Inner Balance's live pages conflict. The refund policy says yes; the HSA/FSA page says no. Get the answer in writing before paying with those funds.
What dose is Oestra?
Inner Balance's main product page lists 3 mg estradiol plus 100 mg progesterone per pump. A help-center page lists 0.5/50 and approximately 2/80 formulations. Confirm the exact milligrams per pump on your prescription before use.
Does Oestra contain testosterone?
The listed ingredients are estradiol and progesterone; the main treatment page says Oestra does not contain added testosterone. Other site copy says progesterone can act as a precursor and describes testosterone "via conversion." That is not the same as Oestra containing testosterone.
Direct testosterone medication in the United States is a Schedule III controlled substance and requires a prescription. It is not listed as an Oestra ingredient.
Is Oestra available in all 50 states?
The public site is inconsistent: different pages say 43 states plus D.C., 48 states, or 50 states. Confirm current eligibility for your state during intake before relying on a national-availability claim.
Does Inner Balance require blood tests?
No laboratory testing is required to start, according to the provider. Optional labs are offered, but public cash prices are not listed. Ask separately about evaluation of unexpected bleeding; that is not answered by a routine hormone blood test.
Is Oestra safe?
A universal yes is not supportable. Estradiol and progesterone are established hormones, but the exact Oestra finished product lacks FDA-reviewed labeling and publicly linked product-specific absorption and endometrial-safety data. Suitability depends on the patient and exact prescription.
Can I use Oestra after a hysterectomy?
Inner Balance lists post-hysterectomy patients as possible candidates. Ask why a fixed progesterone component is needed in your individual case, because the usual HRT role of progestogen is endometrial protection and exceptions require a reason.
Can I use Oestra while breastfeeding?
Oestra has no FDA-reviewed lactation section. Approved estradiol vaginal-cream labeling warns about estrogen exposure during lactation and possible reduction in milk production. A breastfeeding decision needs individual clinician review.
What if I bleed while using Oestra?
If you are 12 or more months past your final period, contact a clinician who can evaluate you. ACOG's 2026 guidance recommends ultrasound plus endometrial tissue sampling as part of the initial evaluation for most patients with postmenopausal bleeding.
Is there an Inner Balance coupon code?
Affiliate codes circulate, but availability changes. This page does not promise a discount that was not verified during the August 10, 2026 audit. Confirm any code at checkout before treating it as part of the price.
What do Inner Balance complaints focus on?
The small external record most often points to cancellation/refund communication, recurring billing, access to a person, identity verification, pump operation, irritation, and dose communication. They are individual reports, not incidence rates.
Should you try Inner Balance?
Inner Balance is a real company selling a real prescription product, and for a narrow woman it can be a sensible route.
One cream. Two hormones. No patch-plus-pill routine. A price that drops after six months. If you already tried FDA-approved options and the routes did not fit—skin reaction, adherence problem, separate products you could not sustain—then individualized compounding is not automatically second best. It may be the entire point.
But do not confuse flexibility with proof.
Inner Balance's own public pages will not currently give you one clean answer on the pharmacy pathway, the dose, HSA/FSA refunds, state coverage, or even every price. Every one of those can be pushed toward certainty with a written answer.
Send the 12 questions. Save the policy. Screenshot the promise. Read your prescription label before the first dose.
That is not being difficult. That is how adults buy medicine.
And if you are postmenopausal and bleeding, need insurance, need an examination, or want a dose you can look up in an FDA-reviewed label, this is not your product. There is no failure in that. There is a route that fits you better.
If the one-combined-cream model is exactly what you came for, and you accept the compounded status with your eyes open: check Inner Balance's current eligibility, price, and state access.
Still not sure which HRT program is right for you? Take our free matching quiz.
Last verified: August 10, 2026. Next scheduled provider-data re-check: September 2026. The top-provider price, policy, availability, and review record should be re-checked monthly.
Educational only. Not medical advice. The HRT Index editorial research — not medically reviewed by a clinician.
Primary sources
Inner Balance commercial facts and policies
- Oestra product page
- Inner Balance HRT treatment page
- Oestra Menopause versus Oestra Start help-center page
- Inner Balance FAQ
- Inner Balance refund policy
- Inner Balance terms and subscription conditions
- Inner Balance HSA/FSA page
- Inner Balance reviews page
- Trustpilot profile for www.innerbalance.com
- BBB business profile
- ConsumerAffairs Inner Balance profile
- Inner Balance page stating 43 states plus D.C.
- Inner Balance page stating 48 states
- Inner Balance page stating all 50 states
- Inner Balance comparison page with a second outcome set
FDA and professional guidance
- FDA: Compounding and the FDA — questions and answers
- FDA: March 3, 2026 warning on misleading telehealth marketing of compounded products
- FDA: Information for outsourcing facilities
- FDA: Registered outsourcing facilities
- FDA: February 12, 2026 menopausal hormone-therapy labeling changes
- The Menopause Society response to the FDA hormone-therapy announcement
- The Menopause Society: Hormone therapy
- The Menopause Society 2022 Hormone Therapy Position Statement summary
- ACOG: Updated guidance on postmenopausal bleeding, April 16, 2026
- PubMed: Stute et al., micronized progesterone and the endometrium
- PubMed: ELITE endometrial analysis of oral estradiol plus vaginal progesterone
- DailyMed: Estradiol vaginal cream 0.01% labeling
- DEA: Drug scheduling, including testosterone as Schedule III